FDA Approves Novo Nordisk Diabetes Drug's Use to Fight Obesity
December 23 2014 - 3:46PM
Dow Jones News
By Maria Armental
Danish drug maker Novo Nordisk A/S's (NVO) injectable diabetes
drug has been approved in the U.S. to fight obesity, the Food and
Drug Administration said Tuesday.
Liraglitude, which is sold as Victoza for diabetes and will be
marketed as Saxenda to fight obesity, is the first once-daily such
treatment, the FDA said.
Trial data submitted to the FDA showed that across all trials,
60% of patients achieved a 5% weight loss and 31% achieved a 10%
weight loss.
The company said the drug's price hasn't been determined.
-Tess Stynes contributed to this article.
Write to Maria Armental at maria.armental@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024